TIDMIIG
RNS Number : 2901E
Intuitive Investments Group plc
29 June 2023
29 June 2023
Intuitive Investments Group plc
Interim report for the six months to 31 March 2023
Intuitive Investments Group plc (AIM: IIG) ("IIG" or the
"Company"), a closed-end investment company focussed on the life
sciences sector, announces its interim results for the six months
to 31 March 2023.
Financial highlights
31 March 30 September 31 March 30 September
2023 2022 2022 2021
GBP9 .42 GBP12.33
Net Assets million GBP12.93 million million GBP8.14 million
GBP7 .86 GBP10.40
Investments million GBP11.16 million million GBP5.74 million
GBP1 .23
Cash million GBP1.55 million GBP1.91 million GBP2.57 million
NAV per share 1 3.07p 18.00p 18.73p 20.14p
% Increase/(decrease)
from previous
period end ( 27.38)% (3.90)% (6.96)% 2.99%
Highlights
-- Follow-on investment in Yourgene Health plc of GBP150,407 to
acquire 50 million shares at a price of 0.3 pence per share. IIG
holds 51,584,920 ordinary shares, or 1.62%, of the issued share
capital of Yourgene.
-- Reorganisation of investment in Sanondaf, reduction in
deferred consideration and adjustment to fair value.
-- Post period end follow-on investment in Light Science
Technologies Holdings plc of GBP150,000 to acquire 15 million
shares at a price of 1 penny per share. IIG holds 28,280,000
ordinary shares, or 8.49%, of the issued share capital of Light
Science Technologies in total.
Intuitive Investments Group plc www.iigplc.com
Julian Baines, Non-Executive Chairman Via SP Angel
Robert Naylor, CEO
SP Angel Corporate Finance LLP
- Nominated Adviser +44 (0) 20 3470 0470
Jeff Keating / David Hignell / Kasia
Brzozowska
Turner Pope Investments (TPI) Ltd
- Broker +44 (0) 20 3657 0050
Andrew Thacker / James Pope
About Intuitive Investments Group plc
The Company is an investment company seeking to provide
investors with exposure to a portfolio concentrating on fast
growing and/or high potential Life Sciences businesses operating
predominantly in the UK, continental Europe and the US, utilising
the Board's experience and in particular that of the chairman of
the Investment Committee, David Evans, to seek to generate capital
growth over the long term for shareholders.
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 ('MAR') which has
been incorporated into UK law by the European Union (Withdrawal)
Act 2018. Upon the publication of this announcement via Regulatory
Information Service ('RIS'), this inside information is now
considered to be in the public domain.
Chairman and Chief Executive's Report
We are pleased to present the interim report for Intuitive
Investments Group plc, which covers the six months ended 31 March
2023.
Publicly traded investments
Publicly quoted small-cap healthcare companies continue to
underperform. We perceive there is a value in the Company's
portfolio and the opportunity for high returns if these companies
are allowed to successfully develop and commercialise their
innovative products or services that meet unmet medical needs.
However, without the ability to raise capital, a number are
destined to struggle regardless of the quality of their products or
services.
We made follow-on investments in Yourgene Health plc
("Yourgene") and, post period end, into Light Science Technology
Holdings ("Light Science") of approximately GBP150,000 each. The
discounts on these follow-on investments to the share prices where
we initially invested were brutal. We originally purchased shares
in Yourgene at a price of 15.5 pence and our follow-on investment
was at 0.3 pence, a discount of 98%. Similarly Light Science
floated at a price of 10 pence per share and our follow-on
investment was at 1 penny, a discount of 90%. Of note is the
investment in Midatech Pharma plc whereby the company's initial
proposed transaction was voted down by shareholders and, as a
consequence, the company had to undertake a highly dilutive rescue
fundraising, in effect wiping out the existing shareholders'
equity. The company has been renamed Biodexa Pharmaceuticals
plc.
Valuation as at
31 March 30 September Unrealised
2023 2022 gain/(loss)
GBP GBP GBP
Evgen Pharma plc 80,937 65,625 15,312
Light Science Technologies
Holding plc 531,200 863,200 (332,000)
Microsaic Systems plc 92,160 88,400 3,760
Biodexa Pharmaceuticals plc
(previously Midatech Pharma
plc) 1,365 26,250 (24,885)
Polarean Imaging plc 89,583 175,000 (85,417)
Shield Therapeutics plc 50,000 75,000 (25,000)
Trellus Health plc 27,625 29,750 (2,125)
Yourgene Health plc(.) (bfwd) 4,359 71,321 (66,962)
Yourgene Health plc. (follow
on investment) (1) 137,500 - (12,907)
----------- -------------- --------------
Closing fair value 1,014,729 1,394,546 (530,224)
(1) Follow o n investment of GBP 150,407 made on 12 January
2023
Unquoted companies
Our portfolio of unquoted companies has performed reasonably in
comparison to the publicly quoted portfolio and continues, in the
main, to be held at cost, plus accrued interest if applicable, or
at the valuation of the most recent investment round. Momentum
Limited has raised additional capital post period end at the same
valuation as the round in which IIG participated and therefore
there is no increase or decrease in valuation. We are aware of one
investee companies currently raising capital which may negatively
impact its valuation. Further details of the companies in the
unquoted portfolio are contained at the end of this statement.
Reorganisation of investment in Sanondaf, reduction in deferred
consideration and adjustment to fair value
As announced on 24 May 2023, the Company has reorganised
Touchless Innovation Limited ("Touchless Innovation") and
Touch-Less Hygiene UK Limited ("Touch-Less Hygiene") (together the
"Touchless Group") which trades under the name Sanondaf and the
Board has negotiated a reduction in the deferred consideration
payable to the vendors of the business and assets of Sanoserv
International Franchising Limited. After careful consideration, the
Board is now proposing reducing in the fair value of the Touchless
Group.
The board of Touchless Innovation , with the agreement of the
board of IIG, moved Touch-Less Hygiene from being a wholly owned
subsidiary of Touchless Innovation to beinga wholly owned
subsidiary of IIG. Touchless Innovation and Touch-Less Hygiene have
different business models. Touchless Innovation is an international
franchising business, with master franchise es in 11 countries.
Touch-Less Hygiene is a UK market-leading provider of specialist
disinfection and decontamination services, with 25 regional sites
in the UK and customers that include blue-chip life sciences
companies, essential infrastructure firms and the NHS. Given the
distinct business models, separating and having distinct management
teams will improve both the opportunity for growth and the
potential to attract third party funding.
The consideration payable by Touchless Innovation to the vendors
included GBP900,000 of deferred consideration payable six months
from completion, due on 25 August 2022. In substitution for the
GBP900,000 the Boards of IIG and Touchless Innovation agreed to
issue the vendors 2,000,000 new ordinary shares of 1 penny each in
IIG, as well as allowing the vendors the master franchise for Malta
for nine years. The minimum royalty amount under the master
franchise agreement is US$5,400 per annum. In addition, the vendors
no longer have the right to appoint a director to the Board of
Touchless Innovation.
The Touchless Group continues to trade profitably and make
significant progress:
-- Touch-Less Hygiene, in selling machines and consumable
product alongside the existing extensive franchise network; and
-- Touchless Innovation has an extensive sales pipeline in the
US which the Board believe will convert to sales imminently.
For the year ended 30 September 2022 the Touchless Group
reported unaudited turnover of GBP1.94 million, profit after tax of
GBP142,000, has net assets of GBP2.24 million including cash of
GBP423,000. The Board has therefore taken the prudent view to
reduce the valuation of the investment in the Touchless Group from
GBP6.36 million to GBP3.50 million, split equally for Touchless
Innovation and Touch-Less Hygiene Touch-Less Hygiene.
Financial performance
NAV per Ordinary Share at; flotation: 18.78 pence; 30 September
2022: 18.00 pence; 31 March 2023: 13.07 pence. Absent the write
down in the Touchless Group the NAV per Ordinary Share would have
been 17.05 pence. There are investment losses of GBP3.44 million,
comprising unrealised losses of GBP3.49 million, interest income
from the convertible loan notes of GBP44,000 and management fee
income of GBP12,000. The structure of the Company is purposefully
simple, and the administrative costs of the business were
GBP193,000 for the period. Overall, the loss for the period was
GBP3.51 million.
Outlook
Despite short term headwinds the Board believer there are
significant opportunities to restore shareholder value. We look
forward to updating you as to our progress in the near term.
Later stage investments
BioQ Pharma Incorporated ("BioQ")
Investment of US$1 million by way of unsecured convertible loan
notes and warrants, valued at cost plus accrued interest.
BioQ has raised more than US$30 million in subscription for the
CLN and is looking to prepare for a fundraising in the Series E
ordinary shares.
BioQ is a commercial-stage, medical device and pharmaceutical
company, addressing the infusible drugs market. BioQ's proprietary
Invenious(TM) platform comprises a "connect-and-go" drug-device
system combination, which can be utilised to improve the delivery
of infusible medicines. BioQ's platform includes a bespoke
unit-dose delivery solution for infusible drugs, whereby a diluent
delivery system and administration line are combined in one
self-contained, ready-to-use presentation. The key benefits of the
platform include reduced cost and complexity compared to current
infusion techniques.
Touchless Innovation Ltd ("Sanondaf")
Investment of GBP1.75 million to acquire the entire issued share
capital, held at fair value, for which cost is which is based on
Directors' valuation.
Touchless Innovation is an international licensing and
franchising business, with master franchise agreements in ten
countries. Sanondaf licenses the brands, know-how and intellectual
property of specialist disinfection and decontamination
technology.
Touch-Less Hygiene Ltd ("Touch-Less Hygiene")
Investment of GBP1.75 million to acquire the entire issued share
capital, held at fair value, which is based on Directors'
valuation.
Touch-Less Hygiene is a market-leading provider of specialist
disinfection and decontamination services and has 25 regional sites
in the UK. Treatments are non-corrosive, contain no toxic
ingredients and Sanondaf's application methods ensure they are not
harmful to people, animals or the environment. It is safe for use
in all settings, including operating theatres, critical care units,
and is CASA (Civil Aviation Safety Authority) approved. Sanondaf's
disinfection formula has proven efficacy against pathogens,
included, viruses, mould, bacteria and fungi. Customers include the
blue-chip life sciences companies, essential infrastructure firms
and the NHS. Touchless Hygiene holds a master franchise agreement
from Touchless Innovation Ltd to operate in the UK.
Series A and B investments
Axol Bioscience Ltd ("Axol")
Investment of GBP249,092 in A ordinary shares, held at fair
value, for which cost is deemed the most appropriate basis of
measurement. The company undertook a fundraising in April 2022 at
the same valuation as IIG's investment.
Axol produces high quality human cell products, particularly in
relation to pluripotent stem cell and critical reagents such as
media and growth supplements, which are sold to medical research
and drug discovery organisations. Axol also provides contract
research for example customising cell lines for customers, such as
reprogramming and differentiation. The Chairman of Axol is Jonathan
Milner, who was previously deputy chairman of Abcam plc.
CardiNor AS ("CardiNor")
Investment of GBP112,891 in ordinary shares, held at fair value,
for which cost is deemed the most appropriate basis of
measurement.
CardiNor has made excellent progress particularly with the
amount of money raised, which includes:
-- Elisa test CE marked with clear route to market in the Europe
and next generation magnetic test being developed.
-- RuO in the US, but distribution deal done with IBL and
talking to Labcorp. Going for full FDA approval.
Valuation is 80 million NOK (c.GBP7.0 million). CardiNor is a
Norwegian biotech company established in June 2015 to commercialise
the development of secretoneurin ("SN"), an important new biomarker
for cardiovascular disease ("CVD"). SN is the only biomarker shown
to be associated with biological processes linked to cardiomyocyte
handling. This unique biological function explains why SN presents
as an independent and strong predictor of mortality in all major
patient cohorts, including ventricular arrhythmia, acute heart
failure, acute respiratory failure patients with CVD and severe
sepsis. CardiNor has completed development of a research assay
based on immunoassay technology to measure SN in blood and the
assay is under further clinical development, allowing it to obtain
a CE mark.
The Electrospinning Company Ltd ("TECL")
Investment of GBP500,000 in ordinary shares, held at fair value,
for which cost is deemed the most appropriate basis of
measurement.
Held at cost, TECL is trading in line with management
expectations. TECL has a technology platform built around the
process of electrospinning, a technique for production of micro and
nano-fibre biomaterials from a variety of natural and synthetic
polymers, and a suite of post-processing technologies to convert
the biomaterials into medical device components. The core business
is the sale of product development and manufacturing services to
medical device companies. TECL is also using its know-how to
develop proprietary materials for targeted out-licensing
opportunities, aiming to capture more of the end-market value
created by its innovations and expertise.
Micrima Ltd ("Micrima")
Investment of GBP229,636 by way of convertible loan note held at
fair value, for which cost is deemed the most appropriate basis of
measurement.
Micrima specialises in radiofrequency technology to improve
early diagnosis of breast cancer and measure breast density.
Micrima continues to make progress, but has suffered delays in its
commercial launch and as a consequence is looking to refocus on
breast density measurement.
Momentum Bioscience Ltd ("Momentum")
Investment of GBP125,000 in preferred A ordinary shares, held at
fair value, for which cost is deemed the most appropriate basis of
measurement. Momentum undertook an additional subscription in
September 2022 at the same valuation as IIG's investment.
Momentum is developing a revolutionary rapid diagnostic test for
patients suspected of sepsis, an infection of the blood stream
resulting in symptoms including a drop in a blood pressure,
increase in heart rate and fever. Momentum's SepsiSTAT(R) system
enables reporting of the presence or absence and 'pan gram
identification' of viable organisms in just two hours, helping
direct the right antimicrobials. The system also provides a pure
concentrate of growing organisms for further analysis. Faster
testing in suspected sepsis patients can reduce mortality,
accelerate hospital discharge, lower hospital costs, and reduce the
incidence of antimicrobial resistance. SepsiSTAT(R) is a diagnostic
test that runs from a sample of whole blood before any culturing
steps are taken and is currently being studied in clinical practice
with highly encouraging early results indicating competitive
sensitivity versus the current standard of care. Over 120 million
blood tests for sepsis are run annually representing a market
potential of over GBP1 billion.
Ocutec Ltd ("Ocutec")
Investment of GBP250,000 in ordinary shares, held at fair value,
for which cost is deemed the most appropriate basis of measurement.
Post period Ocutec completed a fundraising of GBP1.2 million. The
price was GBP2.00 per ordinary share which compares to a price of
GBP1.60 per ordinary share at the time of the Company's investment.
Therefore, there is a post period end unrealised gain of GBP62,500,
based on most recent funding round.
Ocutec has patented technology covering the formulation of novel
contact lens products, contact lens comfort solutions and injection
moulding technology for rapid manufacturing. Ocutec is based in
Glasgow, and has been operating since 2006, having been spun out of
the University of Strathclyde.
PneumoWave Ltd ("PneumoWave")
Investment of GBP904,124 in new ordinary shares, held at fair
value, for which last investment round is deemed the most
appropriate basis of measurement.
IIG invested GBP100,000 by way of convertible loan notes which
converts at a 15% discount to the Series A and GBP350,000 in the
pre-series A funding round. The Series A round has completed
leading to an increase in valuation of GBP454,124.
PneumoWave, which was incorporated in February 2018, is
developing an innovative remote respiratory monitoring platform
comprising a small, chest-worn biosensor and AI-driven data
analysis/alerting software for the early detection, prediction, and
prevention of adverse events in respiratory patients, both in
hospitals and at home. In 2020, PneumoWave was awarded Breakthrough
Medical Device designation from the U.S. Food and Drug
Administration for the development of the device, which is designed
to monitor breathing in real-time to a clinical standard of
care.
The specially designed wireless biosensor is one of the smallest
available and transmits data to the cloud using a data hub or
smartphone, alerting the patient, their household members, doctor,
nurse, or emergency services where life-threatening changes occur.
PneumoWave's technology will be able to accurately monitor large
numbers of patients in any location at any time.
Intuitive Investments Group Plc
Statement of Comprehensive Income
For the 6 months to 31 March 2023
6 months to 6 months Year to
31 March to 30 September
2023 31 March 2022
Unaudited 2022 Audited
Unaudited
GBP'000 GBP'000 GBP'000
Investment income
Finance income 44 99 148
Gains on realised investments - 76 76
Unrealised gains/(losses)
due to FX (96) 166
(Losses)/Gains on investments
at fair value (3,395) (889) (1.493)
Management Fees 12 18 30
-------------- -------------- --------------
(3,435) (696) (1,073)
Administrative expenses (193) (195) (494)
-------------- -------------- --------------
(Loss)/Profit before tax (3,628) (891) (1,567)
Corporation tax 114 174 409
-------------- -------------- --------------
(Loss)/Profit for the period (3,514) (717) (1,158)
Other Comprehensive Income - - -
-------------- -------------- --------------
Total comprehensive income
for the period (3,514) (717) (1,158)
Total comprehensive income
attributable to the owners
of the company (3,514) (717) (1,158)
(Loss) per share
Basic - pence 3 (4.9)p (1.49)p (2.01)p
Diluted - pence (4.9)p (1.49)p (2.01)p
Intuitive Investments Group Plc
Statement of Financial Position
As at 31 March 2023
Notes As at As at As at
31 March 31 March 30 September
2023 2022 2022
Unaudited Unaudited Audited
ASSETS GBP'000 GBP'000 GBP'000
Non-current assets
Investments 4 7,863 10,398 11,160
Deferred tax asset 352 94 238
-------------- -------------- --------------
8,215 10,492 11,398
-------------- -------------- --------------
CURRENT ASSETS
Trade and other receivables 22 43 24
Cash and cash equivalents 1,233 1,911 1,553
-------------- -------------- --------------
1,255 1,954 1,577
-------------- -------------- --------------
TOTAL ASSETS 9,470 12,446 12,975
EQUITY
Shareholders' Equity
Called up share capital 5 721 658 721
Deferred shares 48 48 48
Share premium 12,619 11,631 12,619
Other reserves 144 144 144
Accumulated deficit (4,111) (156) (597)
-------------- -------------- --------------
Total Equity 9,421 12,325 12,935
-------------- -------------- --------------
LIABILITIES
Current liabilities
Trade and other payables 49 30 40
Non current liabilities
Deferred tax liabilities - 91 -
-------------- -------------- --------------
TOTAL LIABILITIES 49 121 40
-------------- -------------- --------------
-------------- -------------- --------------
TOTAL EQUITY AND LIABILITIES 9,470 12,446 12,975
Net asset value per share 13.07p 18.73p 18.00p
Intuitive Investments Group Plc
Statement of Changes in Equity
For 6 months to 31 March 2023
Called Deferred Share Other Retained Total
up Shares Premium Reserves Earnings Equity
Share
Capital
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Balance at 30
September
2021 404 48 6,986 144 561 8,143
Loss for the
period - - - - (717) (717)
Issued share
during
the period 254 - 4,645 - - 4,899
------------ ------------ -------------- ------------ ------------ --------------
Balance at 31
March
2022 658 48 11,631 144 (156) 12,325
Loss for the
period - - - - (441) (441)
Issued share
during
the period 63 - 988 - - 1,051
------------ ------------ -------------- ------------ ------------ --------------
Balance at 30
September
2022 721 48 12,619 144 (597) 12,935
Loss for the
period - - - - (3,514) (3,514)
------------ ------------ -------------- ------------ ------------ --------------
Balance at 31
March
2023 721 48 12,619 144 (4,111) 9,421
------------ ------------ -------------- ------------ ------------ --------------
Intuitive Investments Group Plc
Statement of Cash Flows
For the 6 months to 31 March 2023
Notes 6 Months 6 Months Year to
to to 30 September
31 March 31 March 2022
2023 2022 Audited
Unaudited Unaudited
GBP'000 GBP'000 GBP'000
Profit/(loss) before tax from
continuing operations (3,628) (890) (1,567)
Adjusted by:
Interest income (44) (45) (93)
Gain on disposal - - (74)
Fair value movement 3,491 888 1,326
------------ ------------ ------------
(181) (47) (408)
Changes in working capital
(Increase)/decrease in trade and
other receivables 2 - 18
(Decrease)/increase in trade and
other payables 9 (4) 7
------------ ------------ ------------
Net cash outflow from operating
activities (170) (51) (383)
Cash flows from investing activities
Purchase of investments 4 (150) (1,350) (1,450)
Proceeds from sale of investments - 138 212
------------ ------------ ------------
Net cash (outflow)/inflow from
investing activities (150) (1,212) (1,238)
------------ ------------ ------------
Cash flows from financing activities
Net proceeds from share issues - 607 607
------------ ------------ ------------
Net cash inflow from financing
activities - 607 607
------------ ------------ ------------
Increase/(decrease) in cash and
equivalents (320) (656) (1,014)
Cash and cash equivalents at beginning
of period 1,553 2,567 2,567
------------ ------------ ------------
Cash and cash equivalents at end
of period 1,233 1,911 1,553
1. General Information
Intuitive Investments Group Plc is a com pany incorp orated and
d omiciled in England and Wales. The com pany is listed on the AIM
market of the Lo nd on Stock Exchange (ticker: IIG).
The financial information set out in this Half Yearly report
does not constitute statutory accounts as defined in Section 434 of
the Companies Act 2006. The Company statutory financial statements
for the period ended 30 September 2022, prepared under UK-Adopted
International Financial Reporting Standards ("IFRS"), have been
filed with the Registrar of Companies. The auditor's report on
those financial statements was unqualified and did not contain
statements under Sections 498(2) and 498 (3) of the Companies Act
2006.
Copies of the annual statutory accounts and the Half Yearly
report can be found on the Company's website at
http://www.iigplc.com/ .
2. Basis of preparation
This Half- Yearly report has been prepared using the historical
cost convention, on a going concern basis and under IFRS. The
interim financial statements have been prepared in accordance with
the accounting policies set out in the Annual Report and Accounts
for the year ended 30 September 2022.
3. Earnings per Share
Basic earnings per share is calculated by dividing the earnings
attributable shareholders by the weighted average number of
ordinary shares outstanding during the period.
Reconciliations are set out below:
6 Months 6 Months
to to Year to
31 March 31 March 31 September
2023 2022 2022
Unaudited Unaudited Audited
Basic
Earnings attributable to
ordinary shareholders (3,514,054) (716,516) (1,158,483)
Weighted average number of
shares 72,064,551 48,046,357 57,724,661
Earnings (Loss) per-share
- pence (4.90) p (1.49) p (2.00) p
Diluted
Earnings attributable to
ordinary shareholders (3,514,054) (716,516) (1,158,483)
Weighted average number of
shares 72,064,551 48,046,357 57,724,661
Earnings (Loss) per-share
- pence (4.90) p (1.49) p (2.01)p
As at 31 March 2023 there were 1,962,500 (2022: 1,962,500)
outstanding share warrants.
4. Investments
Cost GBP'000
At 30 September 2021 5,737
Additions during 6 months to 31
March 2022 5,642
Disposals (138)
Accrued interest 44
Change in fair value (887)
------------
At 31 March 2022 10,398
Additions during 6 months to 30
September 2022 1,151
Accrued interest 49
Change in fair value (438)
------------
At 30 September 2022 11,160
Additions during 6 months to 31
March 2023 150
Accrued interest 44
Change in fair value (3,491)
------------
At 31 March 2023 7,863
5. Share Capital
Issued share capital comprises:
6 months 6 months Year to
to to to 31 September
to 31 March to 31 March 2022
2023 2022 Audited
Unaudited Unaudited
GBP'000 GBP'000 GBP'000
Ordinary shares
of 1p each 721 658 721
-------------- -------------- --------------
721 658 721
There were no shares issued during the period.
6. Post balance sheet events
On 1 April 2023 Ocutec Limited completed a fundraising of GBP1.2
million. The price was GBP2.00 per ordinary share which compares to
a price of GBP1.60 per ordinary share at the time of the Company's
investment. Therefore there is an unrealised gain of GBP62,500,
based on most recent funding round.
On 26 April 2023 a follow-on investment in Light Science
Technologies Holdings plc of GBP150,000 was made to acquire 15
million shares at a price of GBP0.01 per share. IIG holds
28,280,000 ordinary shares of Light Science Technologies in
total.
On 30 May 2023 2,000,000 shares of 1 penny each in the Company
were issued at a value of GBP0.055 per share in settlement of the
GBP900,000 deferred consideration payable as part of the
acquisition of Touchless Innovation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IR FPMFTMTBTBIJ
(END) Dow Jones Newswires
June 29, 2023 02:00 ET (06:00 GMT)
Intuitive Investments (LSE:IIG)
Historical Stock Chart
From Apr 2024 to May 2024
Intuitive Investments (LSE:IIG)
Historical Stock Chart
From May 2023 to May 2024
